Enumeral Biomedical Holdings Inc fka ENUMQ

[undtrdr]

PIRS Conference call has some interesting tidbits regarding the licensing agreement and their intent with it going forward ... the Q & A at the end reveals a little further color

http://seekingalpha.com/article/3974584-pieris-pharmaceuticals-pirs-ceo-stephen-yoder-q1-2016-results-earnings-call-transcript

"Our key objectives for 2016 are several and include the completion of our first-in-patient trial for PRS-080 in anemia, which is a prerequisite for establishing proof of concept in our targeted anemia patient population. It also includes continued progress for both PRS-060 in asthma and PRS-343 in HER2 solid tumors, with an anticipated initiation of first-in-man trials for each program in the first half of 2017; continued progress with our immuno-oncology multi-specifics franchise in general, including PRS-342 , working towards developing yet novel therapies with meaningful differentiation over conventional antibody approaches; also includes leveraging our licensing agreement with Enumeral to develop novel PD1-based multi-specific checkpoint blockade offering differentiation over current PD1 antibody approaches, and finally, potentially securing additional partnerships as further validation of our Anticalin drug platform."

From page 6 quotes from PIRS CEO Stephen Yoder:

"With respect to the Enumeral transaction, at the heart of this agreement is our fundamental belief that having an Anticalin antibody-based approach in the PD1 space is something that is very important to have a high value long-term immuno-oncology pipeline."

"So fundamentally, this is about having a best-in-class, potentially multiple best-in-class PD-based approaches, and we’ve already built multiple permutations of PD1 antibody Anticalin fusions with undisclosed but existing Anticalins in the checkpoint space."